Comparison of first-line and second-line use of fingolimod in relapsing MS: The open-label EARLIMS study.
Oscar Fernández, Guillermo Izquierdo, Eduardo Aguera, Cristina Ramo, Miguel Hernandez, Diego Silva, Rob Walker, Helmut Butzkueven, Chenyu Wang, Michael Barnett, undefined EARLIMS investigators
Multiple Sclerosis Journal - Experimental, Translational and Clinical | Published : 2020
Background: Treatment of MS often begins with low-efficacy injectable disease-modifying therapy (iDMT). Objectives: To compare the effect of fingolimod 0.5 mg/day on clinical, MRI, patient-reported, and safety outcomes, in treatment-naïve and previously treated (≥1 iDMT) patients with early MS. Methods: EARLIMS was a multicentre, open-label, non-randomized, parallel-group phase 3 b/4 study in Australia and Spain. Patients with relapsing-remitting MS, Expanded Disability Status Scale (EDSS) score 1 iDMT.